Skip to main content
IC
MedCap AB (publ) (STO:MCAP)
Sweden flag Sweden · Delayed Price · Currency is SEK
443.00
-14.00 (-3.06%)
May 13, 2025, 5:29 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Medtech Revenue (Pre-Q3 2023 Reporting)
1.43B
Log In
Log In
Log In
Log In
Medtech Revenue (Pre-Q3 2023 Reporting) Growth
20.27%
Log In
Log In
Log In
Log In
Specialty Pharma
410.20M
Log In
Log In
Log In
Log In
Specialty Pharma Growth
-14.70%
Log In
Log In
Log In
Log In
Assistive Tech
821.40M
Log In
Log In
Log In
Log In
Assistive Tech Growth
29.15%
Log In
Log In
Log In
Log In
Medtech Revenue (Post-Q2 2023 Reporting)
607.20M
Log In
Log In
Log In
Log In
Medtech Revenue (Post-Q2 2023 Reporting) Growth
10.04%
Log In
Log In
Log In
Log In
Pharmaceuticals
397.30M
Log In
Log In
Log In
Log In
Pharmaceuticals Growth
-17.11%
Log In
Log In
Log In
Log In
Assistive Technology
820.30M
Log In
Log In
Log In
Log In
Assistive Technology Growth
29.36%
Log In
Log In
Log In
Log In
Medical Devices
326.40M
Log In
Log In
Log In
Log In
Medical Devices Growth
17.41%
Log In
Log In
Log In
Log In
Nutrition & Other Food
253.50M
Log In
Log In
Log In
Log In
Nutrition & Other Food Growth
7.28%
Log In
Log In
Log In
Log In
Other Product
40.90M
Log In
Log In
Log In
Log In
Other Product Growth
-0.73%
Log In
Log In
Log In
Log In

EBIT by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Medtech Operating Profit (Pre-Q3 2023 Reporting)
268.10M
Log In
Log In
Log In
Log In
Medtech Operating Profit (Pre-Q3 2023 Reporting) Growth
21.37%
Log In
Log In
Log In
Log In
Specialty Pharma Operating Profit
21.10M
Log In
Log In
Log In
Log In
Specialty Pharma Operating Profit Growth
-71.83%
Log In
Log In
Log In
Log In
Other and Eliminations from Operating Profit
-24.30M
Log In
Log In
Log In
Log In
Other and Eliminations from Operating Profit Growth
-12.27%
Log In
Log In
Log In
Log In
Assistive Tech Operating Profit
171.70M
Log In
Log In
Log In
Log In
Assistive Tech Operating Profit Growth
18.17%
Log In
Log In
Log In
Log In
Medtech Operating Profit (Post-Q2 2023 Reporting)
96.40M
Log In
Log In
Log In
Log In
Medtech Operating Profit (Post-Q2 2023 Reporting) Growth
27.51%
Log In
Log In
Log In
Log In

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Medtech Adjusted EBITDA (Pre-Q3 2023 Reporting)
360.90M
Log In
Log In
Log In
Log In
Medtech Adjusted EBITDA (Pre-Q3 2023 Reporting) Growth
21.97%
Log In
Log In
Log In
Log In
Specialty Pharma Adjusted EBITDA
45.70M
Log In
Log In
Log In
Log In
Specialty Pharma Adjusted EBITDA Growth
-55.33%
Log In
Log In
Log In
Log In
Other and Eliminations from Adjusted EBITDA
-22.20M
Log In
Log In
Log In
Log In
Other and Eliminations from Adjusted EBITDA Growth
-6.33%
Log In
Log In
Log In
Log In
Assistive Tech Adjusted EBITDA
224.00M
Log In
Log In
Log In
Log In
Assistive Tech Adjusted EBITDA Growth
21.67%
Log In
Log In
Log In
Log In
Medtech Adjusted EBITDA (Post-Q2 2023 Reporting)
136.90M
Log In
Log In
Log In
Log In
Medtech Adjusted EBITDA (Post-Q2 2023 Reporting) Growth
22.45%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Sweden
883.80M
Log In
Log In
Log In
Log In
Sweden Growth
3.79%
Log In
Log In
Log In
Log In
Nordic (ex-Sweden)
476.60M
Log In
Log In
Log In
Log In
Nordic (ex-Sweden) Growth
29.48%
Log In
Log In
Log In
Log In
Europe (ex-Nordic)
402.30M
Log In
Log In
Log In
Log In
Europe (ex-Nordic) Growth
1.98%
Log In
Log In
Log In
Log In
Rest of the World
76.10M
Log In
Log In
Log In
Log In
Rest of the World Growth
38.62%
Log In
Log In
Log In
Log In